Self-rated health (SRH) is one of the most frequently used indicators in health and social research. Its robust association with mortality in very different populations implies that it is a comprehensive measure of health status and may even reflect the condition of the human organism beyond clinical diagnoses. Yet the biological basis of SRH is poorly understood. We used data from three independent European population samples (N approx. 15,000) to investigate the associations of SRH with 150 biomolecules in blood or urine (biomarkers). Altogether 57 biomarkers representing different organ domains were found to be associated with SRH, including markers of inflammation, metabolism, and aging. The results suggest that SRH is not only a subjective measure of health but also a reflection of underlying biological processes.
systems were associated with SRH. In almost half of the cases the association was independent of disease and physical functioning. Biomarkers weakened but did not remove the association between SRH and mortality. We propose three potential pathways through which biomarkers may be incorporated into an individual's subjective health assessment, including (1) their role in clinical diseases; (2) their association with health-related lifestyles; and (3) their potential to stimulate physical sensations through interoceptive mechanisms. Our findings indicate that SRH has a solid biological basis and it is a valid but non-specific indicator of the biological condition of the human organism.

Self-rated health (SRH) is one of the most frequently used measures in epidemiological, clinical and social research. It is known to predict mortality, future functional status and outcome of treatment in populations that vary by age, gender, social class, health status, country and culture1-5. In many studies SRH remains a significant predictor of mortality after adjustment for several other health indicators6. However, the wider the array of objectively measured health variables, the weaker is the independent predictive power of SRH7-4. Therefore it is plausible that the association between SRH and mortality is not causal but is due to the ability of the self-assessment to more exhaustively capture the realm of ‘health’ and the objective bodily condition than most other health indicators7-9.

Jylhä (2009) has suggested that when asked to evaluate their general health status, respondents will take into account any individual relevant information that they think describes their ‘health’. This information is then considered in the context of the social and psychological situation. Empirical studies show that individuals will mainly take into account their medical diagnoses and functional status1, but also experienced symptoms, medication and other signs of health problems, and particularly in the absence of any evident health problems, different health-related lifestyles and risk factors6.

A number of studies have found associations between SRH and biomarker levels (i.e. quantities of biomolecules) in blood, such as white cell count, albumin and haemoglobin7, HDL cholesterol7-9, leptin10, TNF-α and IL-1ra11, CD19+ cells and IgG12, CRP13-15, IL-613,16,17, fasting plasma glucose and glycosylated haemoglobin18 and vitamin D19,20. The findings are fragmented, however, as each study usually addresses only a few indicators. Furthermore, most samples have been small, and in many cases other health data have been less than optimal. At least in part, these associations probably reflect the severity and symptoms of chronic diseases. Yet it is possible to hypothesize that the level of and changes in some biomarkers may, through interoceptive processes, be associated with sensations and symptoms that individuals take into account in their self-ratings of health. Overall, little is known about the experiential counterparts of variations in blood biochemistry, although the connections of fatigue with peripheral inflammation for example, are well described21,22.

In order to understand the potential of SRH as a measure of health in clinical practice and research, it is important to know how accurately SRH reflects the condition of the human body. In the present explorative study, we investigated the associations of SRH with a wide array of biomolecule levels measured in blood and urine. These biomarkers provide more detailed information about the condition of the human body than diagnostic names alone as they can reflect the stage and severity of current pathologies as well as the physiological processes taking place in individuals without clinical diagnoses. We hypothesize that the possible association between SRH and biomarkers is largely, but not entirely, explained by diseases and physical functioning, which at least to some extent reflects the severity of diseases. We also hypothesize that the association of SRH and mortality is partly explained by the measured biomarkers. We addressed the following questions: (i) to what extent are the biomarkers available in the study associated with SRH; (ii) to what extent are the associations between biomarkers and SRH explained by disease diagnoses and physical functioning; and (iii) do the biomarkers associated with SRH explain part of the association between SRH and mortality? Analyses i) and iii) were also performed for individuals without diagnosed diseases. We used three extensive population-based data sets: MARK-AGE, the Copenhagen Aging and Midlife Biobank (CAMB), and Health 2000, covering a total of approx. 15,000 individuals and 150 biomarkers.

**Results**

**Participant characteristics.** In MARK-AGE (n = 3,187) 12% rated their health as excellent, 35% as very good, 41% as good, 11% as fair and 1.4% as poor. In CAMB (n = 5,335) the figures were 9.1%, 41%, 40%, 8.6% and 1.4%, respectively. In Health 2000 (n = 6,444) 32% rated their health as good, 30% as rather good, 27% as moderate, 8% as rather poor and 3.5% as poor. Table 1 shows the participants’ characteristics by SRH. In all three data sets poorer SRH was associated with a higher number of diseases and poorer physical functioning (Table 1; Chi-square test: \( p < 0.001 \)).

**Biomarkers associated with SRH.** Out of the 150 biomarkers investigated (Fig. 1A, Supplementary information 1, Supplementary information 2: Table S1 and S2), 57 were significantly associated with SRH in linear regression analyses that were adjusted for age and gender (model i). Table 1 shows the means and medians by SRH for these 57 biomarkers. Eleven of them were available in two or three data sets (Table 2, Supplementary information 2: Table S1 and S2) and they showed similar directions of associations across the data sets. Of the 57 biomarkers, 46 were available for analysis in one data set only (Table 3, Supplementary information 2: Table S1 and S2).

When additionally adjusted for number of diseases and physical functioning (model ii), 26 biomarkers were still associated with SRH. Seven of these biomarkers were available in two or three data sets (Table 2) and 19
| Sample size | **MARK-AGE CAMB Health 2000** | **Self-rated health** | % (N) | % (N) | % (N) | % (N) | % (N) | % (N) |
|-------------|-------------------------------|-----------------------|-------|-------|-------|-------|-------|-------|
| Age         |                               |                       |       |       |       |       |       |       |
| Min–Max, years | 18–92                        | 35–78                 | 48–62 | 49–62 | 30–99 | 30–97 |       |       |
| Mean (Median), years | 57 (59) | 62 (64) | 54 (56) | 54 (56) | 52 (49) | 65 (67) |       |       |
| Male        |                               |                       |       |       |       |       |       |       |
| % (N) | 88 (2798) | 12 (389) | 90 (4799) | 10 (536) | 88 (5679) | 12 (765) |       |       |
| Female      |                               |                       |       |       |       |       |       |       |
| % (N) | 88 (1338) | 12 (177) | 90 (3296) | 10 (363) | 88 (2554) | 12 (349) |       |       |
| Number of diseases |                               |                       |       |       |       |       |       |       |
| No diseases, % (N) | 95 (1572) | 5 (85) | 97 (2418) | 3 (81) | 97 (2489) | 3 (85) |       |       |
| One disease, % (N) | 87 (856) | 13 (131) | 90 (1699) | 10 (195) | 92 (1777) | 8 (163) |       |       |
| Two diseases, % (N) | 73 (280) | 28 (106) | 79 (564) | 21 (153) | 79 (882) | 21 (232) |       |       |
| Three diseases, % (N) | 62 (83) | 39 (52) | 58 (102) | 42 (74) | 71 (397) | 29 (160) |       |       |
| 4 + diseases, % (N) | 32 (7) | 68 (15) | 33 (16) | 67 (33) | 52 (134) | 48 (125) |       |       |
| Difficulties in physical functioning, sum of scores |                               |                       |       |       |       |       |       |       |
| 0, % (N) | 98 (485) | 2 (10) | 98 (1386) | 2.2 (31) | 97 (1766) | 3 (64) |       |       |
| 1 or 2, % (N) | 92 (1584) | 8 (137) | 93 (2915) | 7 (210) | 95 (2907) | 5 (159) |       |       |
| 3 or 4, % (N) | 78 (687) | 22 (193) | 67 (474) | 33 (229) | 76 (259) | 24 (237) |       |       |
| 5 or 6, % (N) | 46 (42) | 54 (49) | 27 (24) | 73 (66) | 46 (259) | 54 (305) |       |       |
| Domain | Concentration of biomarker, unit, mean (median) |                       |       |       |       |       |       |       |
| Amino acid metabolism | Alaine minotransferase, U/l | 24 (22) | 26 (24) | – | – | – | – |       |
| Calcium status | Calcium, mmol/l | – | – | – | – | – | – | – |
| Endocrine function | Leptin, ng/l | – | – | – | – | – | 17 (11) | 22 (15) |
| Glucose metabolism | Glucose, mmol/l | 5.2 (5.1) | 5.7 (5.3) | 5.2 (5.3) | 5.5 (5.4) | 5.5 (5.3) | 6.0 (5.5) |       |
| | Haemoglobin A1C, % | 6.0 (5.9) | 6.3 (6.1) | 5.3 (5.3) | 5.5 (5.5) | 5.3 (5.2) | 5.7 (5.4) |       |
| | Insulin, mU/ml | 6.1 (5) | 8.5 (5.7) | – | – | 9.1 (7.0) | 13 (9.0) |       |
| Immune system | CRP mg/l | 2.1 (1.2) | 3.4 (1.8) | 2.2 (1.1) | 3.9 (1.9) | 2.0 (0.7) | 4.0 (1.4) |       |
| | CMV antibodies, U/l | 39 (22) | 33 (37) | – | – | – | – |       |
| | Tetanus IgG antibodies, IU/ml | 3.7 (1.6) | 2.6 (0.78) | – | – | – | – |       |
| | Rheumatoid factor, IU/ml | – | – | – | – | 19 (15) | 30 (15) |       |

Continued
| Domain | Concentration of biomarker, unit, mean (median) |
|--------|-----------------------------------------------|
|        |                                               |
|        | Lipid metabolism                              |
|        |                                               |
|        | Apolipoprotein-A1, g/l                        | 28 (27) |
|        | Apolipoprotein-B, g/l                         | 27 (26) |
|        | Apolipoprotein-A1, g/l                        | 25 (24) |
|        | Apolipoprotein-B, g/l                         | 24 (23) |
|        | Apolipoprotein-A1, g/l                        | 23 (22) |
|        | Apolipoprotein-B, g/l                         | 22 (20) |
|        | Apolipoprotein-A1, g/l                        | 28 (27) |
|        | Apolipoprotein-B, g/l                         | 27 (26) |
|        | Apolipoprotein-A1, g/l                        | 25 (24) |
|        | Apolipoprotein-B, g/l                         | 24 (23) |
|        | Apolipoprotein-A1, g/l                        | 23 (22) |
|        | Apolipoprotein-B, g/l                         | 22 (20) |
|        | Apolipoprotein-A1, g/l                        | 28 (27) |
|        | Apolipoprotein-B, g/l                         | 27 (26) |
|        | Apolipoprotein-A1, g/l                        | 25 (24) |
|        | Apolipoprotein-B, g/l                         | 24 (23) |
|        | Apolipoprotein-A1, g/l                        | 23 (22) |
|        | Apolipoprotein-B, g/l                         | 22 (20) |
|        | Apolipoprotein-A1, g/l                        | 28 (27) |
|        | Apolipoprotein-B, g/l                         | 27 (26) |
|        | Apolipoprotein-A1, g/l                        | 25 (24) |
|        | Apolipoprotein-B, g/l                         | 24 (23) |
|        | Apolipoprotein-A1, g/l                        | 23 (22) |
|        | Apolipoprotein-B, g/l                         | 22 (20) |
|        | Apolipoprotein-A1, g/l                        | 28 (27) |
|        | Apolipoprotein-B, g/l                         | 27 (26) |
|        | Apolipoprotein-A1, g/l                        | 25 (24) |
|        | Apolipoprotein-B, g/l                         | 24 (23) |
|        | Apolipoprotein-A1, g/l                        | 23 (22) |
|        | Apolipoprotein-B, g/l                         | 22 (20) |
|        | Apolipoprotein-A1, g/l                        | 28 (27) |
|        | Apolipoprotein-B, g/l                         | 27 (26) |
|        | Apolipoprotein-A1, g/l                        | 25 (24) |
|        | Apolipoprotein-B, g/l                         | 24 (23) |
|        | Apolipoprotein-A1, g/l                        | 23 (22) |
|        | Apolipoprotein-B, g/l                         | 22 (20) |
|        | Apolipoprotein-A1, g/l                        | 28 (27) |
|        | Apolipoprotein-B, g/l                         | 27 (26) |
|        | Apolipoprotein-A1, g/l                        | 25 (24) |
|        | Apolipoprotein-B, g/l                         | 24 (23) |
|        | Apolipoprotein-A1, g/l                        | 23 (22) |
|        | Apolipoprotein-B, g/l                         | 22 (20) |
|        | Apolipoprotein-A1, g/l                        | 28 (27) |
|        | Apolipoprotein-B, g/l                         | 27 (26) |
|        | Apolipoprotein-A1, g/l                        | 25 (24) |
|        | Apolipoprotein-B, g/l                         | 24 (23) |
|        | Apolipoprotein-A1, g/l                        | 23 (22) |
|        | Apolipoprotein-B, g/l                         | 22 (20) |
|        | Apolipoprotein-A1, g/l                        | 28 (27) |
|        | Apolipoprotein-B, g/l                         | 27 (26) |
|        | Apolipoprotein-A1, g/l                        | 25 (24) |
|        | Apolipoprotein-B, g/l                         | 24 (23) |
|        | Apolipoprotein-A1, g/l                        | 23 (22) |
|        | Apolipoprotein-B, g/l                         | 22 (20) |
|        | Apolipoprotein-A1, g/l                        | 28 (27) |
|        | Apolipoprotein-B, g/l                         | 27 (26) |
|        | Apolipoprotein-A1, g/l                        | 25 (24) |
|        | Apolipoprotein-B, g/l                         | 24 (23) |
|        | Apolipoprotein-A1, g/l                        | 23 (22) |
|        | Apolipoprotein-B, g/l                         | 22 (20) |
|        | Apolipoprotein-A1, g/l                        | 28 (27) |
|        | Apolipoprotein-B, g/l                         | 27 (26) |
|        | Apolipoprotein-A1, g/l                        | 25 (24) |
|        | Apolipoprotein-B, g/l                         | 24 (23) |
|        | Apolipoprotein-A1, g/l                        | 23 (22) |
|        | Apolipoprotein-B, g/l                         | 22 (20) |
biomarkers in one data set only (Table 3). A schema of the analysis pipeline and summaries of the findings are shown in Supplementary information 2 (Figure S1, Table S1 and S2) and Fig. 1B.

As examples of replicated and new findings representing different biological domains, Fig. 2 shows the associations of eight selected biomarkers, categorized as quartiles, with SRH. Most of these analyses showed a graded association of poorer SRH with poorer biomarker levels.

**Mortality analysis.** In the Health 2000 data the association between SRH and mortality (iii) was analysed using Cox regression analysis. Out of 5,957 participants with a full set of data for relevant variables, 1,207 (20%) died between 2000 and 2015. The average survival time for the deceased participants was 8.1 (SD 4.2) years.
A graded relationship was found between SRH and mortality in models adjusting for age and gender, and then additionally for diseases (Fig. 3). In the third model the analysis was further adjusted for ten biomarkers that were significantly associated with SRH (model ii, results shown in Tables 2 and 3: leptin, apolipoprotein B, cotinine, HbA1C, HDL:total cholesterol ratio, HDL cholesterol, triglycerides, 25-hydroxy-vitaminD, gamma-glutamyltransferase and CRP). The association between SRH and mortality was weakened after the addition of these biomarkers to the model, but it still remained significant: hazard ratios (95% CIs) 1.1 (0.9, 1.4), 1.3 (1.0, 1.5) and 2.0 (1.6, 2.5), respectively.

Analyses for individuals without diseases. All analyses were also conducted separately for subsamples of individuals who had no disease diagnoses (MARK-AGE n = 1657, CAMB n = 2499, Health 2000 n = 2574). Descriptive statistics for these participants are shown in Supplementary information 2: Table S3. In linear regression models adjusted for age and gender, 8 biomarkers that were available for analysis in two or three data sets (p < 0.05 in all data sets) and 8 biomarkers that were available in one data set (Bonferroni-adjusted p value < 0.05) were significantly associated with SRH (Supplementary information 2: Table S1, S4 and S5). As in the results for the whole data, CRP, triglycerides and HDL cholesterol showed a significant association in all three data sets, and vitamin D in the two data sets where it was available. For the biomarkers that in the full data were significantly associated with SRH, with only few exceptions, the direction of the associations was the same among the “healthy” participants, although the associations in the latter group did not always reach statistical significance. Results for all biomarkers from the analysis in healthy individuals are shown in Supplementary information 3.

For the subsample of individuals without diagnoses (n = 2,408) in the Health 2000 data, the association between SRH and mortality was analysed using Cox regression analysis. During the 15-year follow-up the number of deaths was 193 (8%), and average survival time for the deceased participants in this sample was 9.2 (SD 4.0) years. In this subsample SRH was a significant dose-responsive predictor of mortality (Supplementary information 2: Figure S2). When the biomarkers that showed a significant association with SRH in the full data analysis (Table 2 and 3, model ii) were included in the model, and when good SRH was set as the reference category, hazard ratios (95% CIs) for rather good, moderate and poor SHR were 1.2 (0.9, 1.7), 1.3 (0.9, 1.9) and 2.3 (1.5, 3.8), respectively.
Table 2. Associations between biomarkers and SRH in linear regression analysis, adjusted for (i) age and gender and (ii) additionally for number of diseases and physical functioning. CRP C-reactive protein, CV cardiovascular, HDL high-density lipoprotein, IU international unit, IL interleukin, LDL low-density lipoprotein, OH hydroxyl, UVB ultraviolet B light, VLDL very low-density lipoprotein. This table presents the results for all biomarkers (n = 17) available in two or three data sets (MARK-AGE, CAMB, and/or Health 2000). Criteria for significant association of a biomarker was \( p < 0.05 \) in all data sets where it was analysed. p-values less than 0.05 are shown in bold. Results for all biomarkers are shown in Supplementary information 1.

| Domain                        | Biomarker                | MARK-AGE | CAMB | Health 2000 |
|-------------------------------|--------------------------|----------|------|-------------|
|                               | \( \beta_0 \) | \( p_1 \) | \( \beta_2 \) | \( p_2 \) | \( \beta_3 \) | \( p_3 \) | \( \beta_4 \) | \( p_4 \) | \( \beta_5 \) | \( p_5 \) | \( \beta_6 \) | \( p_6 \) | \( \beta_7 \) | \( p_7 \) |
| Muscle metabolism; renal health | Creatinine              | –0.0011  | 0.24  | –0.0012  | 0.15  | – | – | – | – | –0.00062 | 0.50  | –0.0016  | 0.046 |
|                               | Creatinine in urine      | 0.00091  | 0.75  | 0.0030  | 0.24  | – | – | – | – | –0.00079 | 0.74  | 0.00084  | 0.69  |
| Glucose and lipid metabolism  | Adiponectin              | –0.0058  | 0.012 | –0.0028 | 0.18  | – | – | – | – | –0.0016  | 0.53  | –0.00050 | 0.82  |
| Glucose metabolism            | Insulin                  | 0.014    | \(< 0.001\) | 0.0059 | 0.003 | – | – | – | – | –0.0011  | 0.007 | 0.00036  | 0.32  |
|                               | Glucose                  | 0.089    | \(< 0.001\) | 0.043 | \(< 0.001\) | 0.047 | \(< 0.001\) | 0.0092 | 0.17 | 0.063    | \(< 0.001\) | 0.015 | 0.086    |
|                               | Haemoglobin AIC, %       | 0.18     | \(< 0.001\) | 0.080 | \(< 0.001\) | 0.21 | \(< 0.001\) | 0.072 | \(< 0.001\) | 0.18 | \(< 0.001\) | 0.075 | \(< 0.001\) |
| Iron metabolism               | Ferritin                | 0.00025  | 0.18  | 0.00010 | 0.54  | – | – | – | – | –0.00055 | \(< 0.001\) | 0.00041 | \(< 0.001\) |
| Lipid metabolism              | HDL;Total cholesterol   | –0.011   | \(< 0.001\) | –0.0080 | \(< 0.001\) | –0.0089 | \(< 0.001\) | –0.0068 | \(< 0.001\) | –0.0098 | \(< 0.001\) | –0.0069 | \(< 0.001\) |
|                               | HDL Cholesterol         | –0.33    | \(< 0.001\) | –0.16  | \(< 0.001\) | –0.27 | \(< 0.001\) | –0.16  | \(< 0.001\) | –0.24 | \(< 0.001\) | –0.10  | 0.011    |
|                               | Cholesterol, total      | –0.074   | \(< 0.001\) | –0.015 | 0.31  | –0.034 | \(< 0.001\) | –0.0045 | 0.60 | –0.015   | 0.12  | 0.023    | 0.018    |
|                               | LDL Cholesterol         | –0.062   | \(< 0.001\) | –0.010 | 0.55  | –0.027 | 0.039    | 0.0080 | 0.49 | –0.029   | 0.014 | 0.017    | 0.11     |
|                               | Triglycerides           | 0.0020   | \(< 0.001\) | 0.0011 | \(< 0.001\) | 0.092 | \(< 0.001\) | 0.044  | \(< 0.001\) | 0.10  | \(< 0.001\) | 0.054  | \(< 0.001\) |
| Nutrition; UVB exposure       | 25-OH-VitaminD          | –0.052   | \(< 0.001\) | –0.0040 | \(< 0.001\) | – | – | – | – | –0.0064  | \(< 0.001\) | –0.0026  | \(< 0.001\) |
| Nutrition (alcohol problem); liver function | Glutamyl trans-ferase | 0.0022   | \(< 0.001\) | 0.0013 | 0.009 | – | – | – | – | –0.0022  | \(< 0.001\) | 0.0016  | \(< 0.001\) |
| One-carbon metabolism; CV health | Homocysteine           | 0.0070   | 0.008 | 0.0026 | 0.28  | – | – | – | – | 0.018    | \(< 0.001\) | 0.0056  | 0.019    |
| Immune system                 | CRP                     | 0.035    | \(< 0.001\) | 0.020 | \(< 0.001\) | 0.028 | \(< 0.001\) | 0.011  | \(< 0.001\) | 0.016 | \(< 0.001\) | 0.0053 | 0.004    |
| Oxygen transfer               | Haemoglobin             | –0.0052  | 0.30  | –0.0028 | 0.52  | 0.044 | 0.012    | 0.014  | 0.35  | 0.0011  | 0.27  | 0.0018  | 0.039    |

Discussion
The underlying assumption of this work was that SRH is a more comprehensive and sensitive indicator of the condition of the human organism than medical diagnoses or measures of physical functioning alone. We hypothesized that if this was true, SRH should show an association with blood and urine biomarkers that reflect the physiological regulation of the organism. Therefore, we analysed 150 biomarkers from almost 15,000 participants enrolled in three population-based studies. Altogether 57 biomarkers showed a significant association with SRH, and for 26 of them the association was upheld when the number of chronic diseases and physical functioning were taken into account. In subsamples of individuals without chronic diseases, 16 biomarkers were associated with SRH. These associations were almost exclusively in a logical direction, i.e. a “worse” biomarker level was associated with poorer SRH and vice versa. Moreover, biomarkers weakened the association between SRH and mortality.

We had no a priori hypothesis as to which biomarkers are important regarding SRH. In this explorative study we included all blood and urine measures that were available in the study samples. Our results confirm the previous evidence for most biomarkers that have been reported to be associated with SRH, and they additionally reveal a large number of new associations. These biomarkers are descriptive of various biological systems of the human body, including inflammation (e.g. CRP), lipid and glucose metabolisms (e.g. cholesterol and HbA1C), oxidative stress (e.g. protein carbonyls) and tissue damage (cell-free DNA), as well as of lifestyles and environmental exposures (e.g. carotenoids, vitamin D, cotinine). Many of the biomarkers associated with SRH are also known to be biomarkers of ageing.23

When selected biomarkers—CRP, HDL cholesterol, HbA1C, 25-hydroxyl-vitamin-D, zeaxanthin, apolipoprotein-B, cell-free DNA and protein carbonyls—were picked up as examples and examined as quartiles, poorer biomarker levels were fairly consistently associated with higher odds for poorer SRH in all data sets (Fig. 2). CRP is a proinflammatory marker and known to be associated with SRH13–15. A few studies have also reported an association between poorer SRH and lower HDL cholesterol9,18 and higher HbA1C19 levels. In our study lower vitamin D level was associated with poorer SRH in both data sets where it was available, and a similar,
| Domain                                | Biomarker                                      | Data set          | $\beta_i$ | $p_i$   | $+\text{physical functioning and number of diseases}$ | $\beta_0$ | $p_0$   |
|--------------------------------------|------------------------------------------------|-------------------|----------|---------|------------------------------------------------------|----------|---------|
| Selenium metabolism                  | Selenium                                      | MARK-AGE          | -0.00564 | $8.28 \times 10^{-16}$ | -0.00433, $9.24 \times 10^{-12}$ |
| Selenium metabolism                  | Selenium bound to Albumin or Selenoprotein P  | MARK-AGE          | -0.00645 | $5.84 \times 10^{-16}$ | -0.00490, $1.15 \times 10^{-11}$ |
| Smoking exposure                     | Cotinine                                      | Health 2000       | 0.000382 | $7.33 \times 10^{-14}$ | 0.000294, $1.41 \times 10^{-10}$ |
| Nutrition                            | Lutein                                        | MARK-AGE          | 0.663    | $2.12 \times 10^{-12}$ | -0.526, $5.88 \times 10^{-10}$ |
| Nutrition                            | Beta-cryptoxanthin                            | MARK-AGE          | -0.421   | $7.01 \times 10^{-14}$ | -0.308, $1.27 \times 10^{-09}$ |
| Endocrine function                   | Leptin                                        | Health 2000       | 0.00892  | $1.82 \times 10^{-26}$ | 0.00375, $1.11 \times 10^{-06}$ |
| Nutrition                            | Beta-carotene                                 | MARK-AGE          | -0.251   | $2.39 \times 10^{-16}$ | -0.135, $1.20 \times 10^{-06}$ |
| Lipid metabolism                     | Apolipoprotein-B                              | Health 2000       | 0.177    | $4.02 \times 10^{-05}$ | 0.180, $3.10 \times 10^{-06}$ |
| Lipid metabolism                     | VLDL1 (large particles) Cholesterol           | MARK-AGE          | 0.0110   | $1.81 \times 10^{-12}$ | 0.00658, $3.44 \times 10^{-06}$ |
| Lipid metabolism                     | VLDL1 Triglycerides                           | MARK-AGE          | 0.00242  | $3.65 \times 10^{-13}$ | 0.00132, $1.39 \times 10^{-05}$ |
| Lipid metabolism                     | VLDL1 (large particles) Triglycerides         | MARK-AGE          | 0.00253  | $1.45 \times 10^{-12}$ | 0.00138, $2.15 \times 10^{-05}$ |
| Lipid metabolism                     | VLDL1 Cholesterol                             | MARK-AGE          | 0.00686  | $2.93 \times 10^{-11}$ | 0.00394, $2.47 \times 10^{-05}$ |
| Lipid metabolism                     | VLDL2 (small particles) Triglycerides         | MARK-AGE          | 0.0229   | $3.60 \times 10^{-13}$ | 0.0119, $3.58 \times 10^{-05}$ |
| Protein modification                 | N-glycosylation status of serum proteins, peak 9 | MARK-AGE          | 0.0577   | $1.26 \times 10^{-05}$ | 0.0462, $9.70 \times 10^{-05}$ |
| Tissue damage                        | Cell-free DNA                                 | MARK-AGE          | -3.42    | $1.06 \times 10^{-11}$ | -2.06, $5.98 \times 10^{-06}$ |
| Lipid metabolism                     | LDL1 (large particles) Cholesterol            | MARK-AGE          | -0.00515 | $2.13 \times 10^{-15}$ | -0.00233, $0.000108$ |
| Nutrition                            | Retinol                                       | MARK-AGE          | -0.145   | $8.15 \times 10^{-05}$ | -0.126, $0.000154$ |
| Immune system                        | Cytomegalovirus antibodies                    | MARK-AGE          | 0.00182  | $1.05 \times 10^{-07}$ | 0.00113, $0.000235$ |
| Purine metabolism                    | Urate                                         | Health 2000       | 0.00129  | $5.02 \times 10^{-14}$ | 0.000205, $0.190$ |
| Lipid metabolism                     | HDL2 (small particles) Triglycerides          | MARK-AGE          | 0.0570   | $3.16 \times 10^{-13}$ | 0.0240, $0.000805$ |
| Lipid metabolism                     | HDL1 Cholesterol, NMR                         | MARK-AGE          | -0.00561 | $8.12 \times 10^{-09}$ | -0.00285, $0.00125$ |
| Nutrition                            | Trigone-line in urine                         | MARK-AGE          | -0.0913  | $8.78 \times 10^{-09}$ | -0.0469, $0.00112$ |
| Creatine metabolism                  | Guanidinocacetate (3–97a) in urine            | MARK-AGE          | -0.0139  | $2.39 \times 10^{-08}$ | -0.00604, $0.00753$ |
| Nutrition                            | Hippurate in urine                            | MARK-AGE          | -0.00894 | $2.61 \times 10^{-08}$ | -0.00396, $0.00663$ |
| Lipid metabolism                     | LDL2 (small particles) Triglycerides          | MARK-AGE          | 0.00229  | $1.84 \times 10^{-07}$ | 0.0126, $0.00148$ |
| Lipid metabolism                     | HDL1 (large particles) Cholesterol            | MARK-AGE          | -0.00592 | $3.45 \times 10^{-07}$ | -0.00283, $0.00715$ |
| Lipid metabolism                     | HDL2 (small particles) Cholesterol            | MARK-AGE          | -0.0129  | $6.50 \times 10^{-07}$ | -0.00731, $0.00174$ |
| Lipid metabolism                     | LDL2 Cholesterol, NMR                         | MARK-AGE          | -0.00243 | $2.26 \times 10^{-06}$ | -0.000635, $0.176$ |
| Transporter protein                  | Albumin in urine                              | Health 2000       | 0.000491 | $5.83 \times 10^{-06}$ | 0.0006643, $0.512$ |
| Immune system                        | Tetanus IgG antibodies                        | MARK-AGE          | -0.0132  | $6.35 \times 10^{-06}$ | -0.00871, $0.00904$ |
| Lipid metabolism                     | VLCL2 (small particles) Cholesterol           | MARK-AGE          | 0.0171   | $6.59 \times 10^{-06}$ | 0.0103, $0.00254$ |
| Aminosaid metabolism                 | Alanineaminotransferase                      | MARK-AGE          | 0.00685  | $7.76 \times 10^{-06}$ | 0.00337, $0.0149$ |
| Calcium status                       | Calcium                                       | Health2000        | 0.652    | $1.21 \times 10^{-05}$ | 0.210, $0.118$ |
| Lipid metabolism                     | HDL2 Triglycerides                            | MARK-AGE          | 0.00169  | $1.32 \times 10^{-05}$ | 0.00684, $0.0504$ |
| Protein modification                 | N-glycosylation status of serum proteins, peak 3 | MARK-AGE          | -0.0424  | $2.35 \times 10^{-05}$ | -0.0261, $0.0039$ |
| Oxidative stress                     | Protein carboxylides                          | MARK-AGE          | 0.704    | $2.94 \times 10^{-05}$ | 0.537, $0.0004$ |
| Nutrition                            | Alpha-carotene                                | MARK-AGE          | -0.333   | $3.03 \times 10^{-05}$ | -0.0743, $0.304$ |
| Tissue repair and revascularization  | Fibrinogen                                    | MARK-AGE          | 0.0469   | $3.86 \times 10^{-05}$ | 0.0256, $0.0125$ |
| Selenium metabolism                  | Selenium bound to Glutathione Peroxidase     | MARK-AGE          | -0.0117  | $4.82 \times 10^{-05}$ | -0.00891, $0.000565$ |
| Lipid metabolism                     | Apolipoprotein-A1                             | Health 2000       | -0.177   | $4.90 \times 10^{-05}$ | -0.0469, $0.231$ |
| Protein modification                 | N-glycosylation status of urinary proteins, peak 6 | MARK-AGE          | 0.0343   | $8.28 \times 10^{-05}$ | 0.0254, $0.00119$ |
| Lipid metabolism                     | Apolipoprotein J/Clusterin                    | MARK-AGE          | 0.00310  | $9.39 \times 10^{-05}$ | 0.00159, $0.0264$ |
| Lipid oxidation product              | 8-isoprostane metabolite, in urine            | MARK-AGE          | 0.0184   | $0.000104$ | 0.00804, $0.0600$ |

Continued
A strong association was also seen among individuals without chronic conditions. Previous studies with smaller

Table 3. Associations between biomarkers and SRH in linear regression analysis, adjusted for (i) age and
gender and (ii) additionally for number of diseases and physical functioning. CRP C-reactive protein, HDL high-density lipoprotein, LDL low-density lipoprotein, NMR nuclear magnetic resonance, VLDL very low-density lipoprotein. The Table shows 46 biomarkers that were available for analysis in one data set only and were associated with SRH in Model (i), 19 of them were associated with SRH also in Model (ii). The results for all biomarkers are shown in Supplementary information 1. Statistical significance level was at Bonferroni-adjusted p value of 0.05, and p values below this threshold are shown in bold.

Figure 2. Associations of the eight selected biomarkers, categorized as quartiles, with poor self-rated health. Odds ratios (ORs) and 95% confidence intervals (CIs) are from the logistic regression models, adjusted for age and gender. The “best” biomarker quartile was used as reference category. (A–H): C-reactive protein (CRP), high-density lipoprotein (HDL) cholesterol, haemoglobin A1C (HBA1C), 25-hydroxyl-vitamin-D (25-OH-vitaminD), zeaxanthin, apolipoprotein-B (Apo-B), cell-free DNA (cf-DNA) and protein carbonyls, respectively. The biomarkers were selected as examples of replicated and new associations representing different biological domains.

Figure 3. Association of self-rated health with mortality in the Health 2000 data (n = 5,957; deceased n = 1,207; 15-year follow-up). In Cox proportional hazards models (iii) hazard ratios (HRs) and 95% CIs were adjusted for (1) age and gender; (2) then additionally for number of diseases; and then (3) additionally for 10 biomarkers.
samples have likewise shown an association between vitamin D and SRH\textsuperscript{19,20}. Recent studies have connected low vitamin D concentration with multiple extra-skeletal processes such as cancer progression, coronary heart disease, depression and a range of immune functions\textsuperscript{24–26}. The mechanisms of these associations are not well known, but it has been suggested that low vitamin D level should be understood as a marker of ill health rather than a causal factor\textsuperscript{27,28}.

This is the first study to report associations between SRH and e.g. zeaxanthin, apolipoprotein-B, cell-free DNA and protein carboxyls. Zeaxanthin is a carotenoid pigment present in the eye and obtained from the diet (e.g. egg yolk and orange peppers)\textsuperscript{29}. It has antioxidative properties and is suggested to have a protective role against eye diseases (especially age-related macular degeneration) as well as cardiovascular diseases and cancer\textsuperscript{30}. Apolipoprotein B is mostly known as the LDL carrier protein, and it is an important contributor to atherosclerosis and cardiovascular disease\textsuperscript{31}. Circulating cell-free DNA is a marker of cellular death and tissue damage in many acute and chronic conditions (e.g. sepsis, trauma, aseptic inflammation, cardiovascular diseases and cancer)\textsuperscript{32–37}. Elevated levels of protein carboxyls (i.e. plasma protein oxidation levels) are a marker of oxidative stress and observed in various pathologies such as Alzheimer’s disease, rheumatoid arthritis, diabetes, sepsis, renal dysfunction and respiratory failure\textsuperscript{38}.

We suggest that there are three main pathways through which biomarkers measured in blood or urine can affect SRH. First, several biomarkers are characteristics of clinical diagnoses. For certain biomarkers such as cholesterol or glucose levels the role is well-known as is their significance as risk factors of disease. Individuals who are asked to rate their own health may be inclined to interpret high values (if they know them) as signs of poorer health. Yet respondents may not necessarily consider their biomarker levels or even be aware of them when asked to assess their health, but instead consider their disease diagnoses, symptoms or decreased physical functioning caused by their diseases. In this case the association between biomarkers and SRH is indirect and mediated by the association of SRH with diseases known to the respondents. This hypothesis for disease pathway is supported by the finding that associations between biomarkers and SRH were more marked among individuals with disease than those without.

Second, it is known that particularly individuals without major health problems take account of health-related lifestyles and behavioural risk factors as components of SRH\textsuperscript{6,39}. In the present study better SRH was associated with higher levels of carotenoids (zeaxanthin, beta-carotene, lutein, beta-cryptoxanthin and beta-carotene) in plasma, and hippurate and trigonelline in urine. These molecules serve as markers of fruit and vegetable intake. Worse SRH was associated with higher cotinine and gamma-glutamyltransferase levels, which serve as markers for smoking exposure and alcohol consumption, respectively. Again it is plausible that the route from biomarkers to SRH is indirect, i.e. that respondents assess their health as good or poor not on the basis of their biomarker levels but rather particular health-related lifestyles that are considered healthy or unhealthy.

Third, an interesting but poorly understood mechanism is the possibility that a biomarker level or change in biomarker level in the body might stimulate physical sensations, and that these sensations are interpreted as information about the state of one’s health. This is not a novel hypothesis but was suggested by Stenback as early as 1964 and later by Kaplan and Camacho in 1983 as one potential explanation for the association between SRH and mortality\textsuperscript{40–42}. Since these studies, research has continued to accumulate about the interoceptive processes through which information on internal states of the body is communicated to the brain to enable the regulation of vital inner processes and the maintenance of physiological stability\textsuperscript{21,43–45}. Most of the research data on interoceptive signalling of humoral processes, i.e. changes in blood substance levels, concerns inflammation: higher circulating levels of inflammatory biomarkers, cytokines, are known to underlie symptoms such as fatigue, general malaise, poor appetite and low mood\textsuperscript{11,12}, and they are known to be associated with poor SRH\textsuperscript{46,47}. In our study, higher levels of inflammatory markers such as CRP and IL-18 showed associations with poor SRH, and for CRP this was true in all three data sets independently of diseases and physical functioning. Yet the empirical evidence on interoceptive signalling of humoral processes remains haphazard and for other blood-measured substances than inflammatory markers almost non-existent.

In our study, as in many previous ones, SRH showed a strong, robust association with mortality. Poorer SRH predicted mortality even after adjusting for chronic conditions in the total sample and in the subsample without chronic conditions. Adjusting for biomarkers weakened this association in both situations, which supports our initial hypothesis.

We were able to utilize three large population-based data sets from multiple European countries, but, unfortunately, not all biomarkers were available in more than one data set, which would allow the principles of conventional replication studies. For some of the biomarkers investigated the association with SRH had already been reported earlier. The strengths of our study included the fact that we had access to a large number of new biomarkers; that several of them were available in more than one data set; that we had access to data on chronic conditions and physical functioning; and that in one sample it was also possible to investigate mortality. Multimorbidity indicated by the number of disease diagnoses is an effective descriptive of health and has prognostic value\textsuperscript{48–49}. In our analysis, the six clinical diagnoses available in the three study samples were common and chronic. However, several important diagnostic categories were absent from our analysis, and we had no information on disease severity other than physical functioning. Therefore, the data available was not ideal to adjust for disease. These are the major limitations of the study. In our exploratory analyses, linear regression models were used to provide an easily understandable overview on the associations of SRH, basically an ordinal variable, with biomarkers; this approach is consistent with several earlier studies, and based on observed continuity in its association with many other health variables. Further, because of the explorative approach, we decided not to construct organ-specific or cluster-based groupings of the biomarkers, and as the role of individual biomarkers in connection to SRH is not known, we decided to include all available measures in our analyses without selection. The mechanisms linking biomarkers with SRH were also beyond the scope of this study. Further studies are needed to shed light on the full pathways between SRH and the biological state of the body.
In conclusion, our study demonstrated strong and logical associations of SRH with numerous biomarkers measured in blood and urine, even independently of chronic diseases and functional status. Poorer SRH was associated with worse biomarker levels and vice versa. These biomarkers were descriptive of many different organ systems and bodily processes. The findings suggest that SRH has a solid biological basis. Our results also lend support to the notion that SRH is a robust, comprehensive but non-specific indicator that can more exhaustively capture health-related processes than many conventional measures of health and disease. To verify the potential of SRH in research and in clinical practice, multidisciplinary research is needed to explore the mechanisms that convey messages from body biology to individuals’ subjective assessments.

Methods

Study populations. In MARK-AGE, questionnaires and interviews were conducted and biological data collected between 2008 and 2012 at the following recruiting centres: Hall in Tyrol/Innsbruck (Austria), Namur (Belgium), Esslingen (Germany), Athens and surrounding regions (Greece), Bologna (Italy), Warsaw (Poland), Tampere (Finland) and Leiden (The Netherlands)50,51. The total number of participants in this analysis was 3,187 (age range 18–92 years).

CAMB collected questionnaire data and biological samples from 5,335 participants (age range 48–62 years) in 2009–2011. This data set comprises participants from three cohort studies: the Metropolit 1953 Danish Male Birth Cohort (MP), the Copenhagen Perinatal Cohort (CPC) born in 1959–1961, and the Danish Longitudinal Study on Work, Unemployment and Health (DALWUH) born in 1949 or 195952.

Health 2000 is a nationwide survey conducted in 2000–2001 with a randomly selected sample (n = 8,028) of the Finnish population aged 30 years or over53. For this analysis we used a subsample of 6,444 participants (age range 30–99 years) with relevant information

No human participants were directly involved in the current study and only data was taken for the current study.

Measures. SRH was assessed in interviews and questionnaires. In MARK-AGE and CAMB, SRH was inquired by asking: "In general, would you say your health is…?", and in Health 2000 by asking: "Is your present state of health…?". The response options were "poor", "fair", "good", "very good" or "excellent" (CAMB and MARK-AGE) and "poor", "rather poor", "moderate", "rather good" or "good" (Health 2000). In linear regression models, SRH was used as a continuous variable ranging from 0 to 4, with a higher value referring to poorer SRH. For the other analyses, the two poorest SRH categories (poor & fair in MARK-AGE and CAMB; poor & rather poor in Health 2000) were combined into one. Then, as an outcome in logistic regression analyses (in Fig. 2), SRH was dichotomized as poor versus all other categories. In mortality analysis (Health 2000) SRH was grouped into four categories: (1) good, (2) rather good, (3) moderate and (4) poor.

A total of 150 biomarkers measured in blood and urine were available for analysis (full list shown in Supplementary information 1): 134 biomarkers in MARK-AGE, 14 in CAMB, and 28 in Health 2000. All measurements were carried out in accordance with relevant guidelines and regulations. Altogether 17 biomarkers were available in two or three of the study populations. A few biomarkers were measured with two different but equivalent measurements. The proportion of missing biomarker data ranged from 0.05 to 25%. A few biomarkers representing different biological domains were selected for inclusion in Fig. 2 as examples of previously shown and new associations with SRH. For this illustration, biomarker levels were categorized as quartiles.

The indicator of physical functioning came from interviews, questionnaires and hand grip strength measurements. A summary variable for physical functioning was constructed out of three components: (1) ability to walk 0.5 mile (in MARK-AGE), 0.25 mile (in CAMB) or 0.5 km (in Health 2000); (2) ability to run 100 m (in CAMB and Health 2000) or do vigorous activities such as running, lifting heavy objects, participating in strenuous sports (in MARK-AGE); and (3) hand grip strength (MARK-AGE, CAMB, Health 2000). In each of these three components, more points corresponded to poorer functioning. The components of walking and running & vigorous activities were scored as 0 = no limitations, 1 = moderate limitations and 2 = highly limited or cannot do at all. Hand grip strength was grouped in tertiles (categories 0, 1 and 2). The scores from the three components were added together to obtain a sum score of physical functioning, ranging from 0 to 6.

Disease diagnoses, including cardiovascular diseases, hypertension, diabetes, cancer/tumour, respiratory diseases and arthritis were obtained from interview and questionnaire data. The variable “number of diseases” ranged from 0 to 6 diseases, but in the final analyses it was categorized as 0, 1, 2, 3 or 4 + diseases. In addition, subsamples with participants without any of the above mentioned diagnoses were extracted in each data set (MARK-AGE n = 1,657; CAMB n = 2,499; Health 2000 n = 2574; characteristics in Supplementary information 2: Table S3).

Mortality data were only available for the Health 2000 sample. Dates of death were drawn from the National Register on Causes of Death maintained by Statistics Finland, and the length of follow-up was 15 years.

Statistical analysis. The association between each individual biomarker and SRH was first explored using linear regression analysis in the three independent cross-sectional data sets (MARK-AGE, CAMB and Health 2000). SRH was the dependent variable, and the models were adjusted for (i) age as a continuous variable and gender, and (ii) additionally for the number of diseases and physical functioning. All MARK-AGE analyses were adjusted for recruitment centre. The nominal p-value threshold was set at 0.05 for biomarkers that were available in two or three data sets (specifically, it was required that the p-value threshold had to be met in all data sets), and, to control the multiple testing problem, at Bonferroni-adjusted p-value of 0.05 for biomarkers that were available in one data set only. Additionally, logistic regression models were used to analyse the associations of...
eight selected biomarkers, categorized as quartiles, with poor SRH, adjusted for age and gender. The results of the eight selected biomarkers were visualized as forest plots (Fig. 2).

Next, the association of SRH with all-cause mortality in the Health 2000 data set was analysed using Cox proportional hazard modelling (iii). The model was adjusted for (1) age and gender; (2) additionally for number of diseases; and (3) furthermore additionally for the biomarkers that were associated with SRH in the linear regression analysis (Model ii). The nominal p-value threshold was set at 0.05. These results were visualized as forest plot (Fig. 3).

Finally, we repeated the analyses of the associations between SRH and the biomarkers in all three data sets and the mortality analysis in the Health 2000 data in subsamples without disease diagnoses. The criteria for statistical significance were the same as in the main analysis.

The data was processed, analysed and visualized using R software (R 3.4.0) and IBM SPSS software version 24.0 (IBM Corp., Armonk, New York, USA). In each model, participants with missing data for a biomarker, mortality, age, gender, SRH, physical functioning or number of diseases were excluded from the analyses.

Ethics approval. Human participants were not directly involved in the current study and only existing data was taken for the current analysis. The study was conducted in accordance with the Declaration of Helsinki ethical principles and all research participants gave their informed consent to be part of the study. The studies (MARK-AGE, CAMB, Health 2000) were approved by the local ethics committees.

Data availability

The data used in the current study are not publicly available for ethical reasons. However, data are available upon request from the Health 2000 survey, MARK-AGE and CAMB for researchers who meet the criteria for access to confidential data. Data from the MARK-AGE study are available from the MARK-AGE steering committee (contact: Alexander Bürkle, alexander.buerkle@uni-konstanz.de). Data from CAMB are available from the Copenhagen Aging and Midlife Biobank steering committee (https://camb.ku.dk/, contact: Rikke Lund, rllu@sund.ku.dk). Health 2000 data are available from THL on request, subject to the submission of approved study proposals and a data transfer agreement (contact: terveys-2000-2011@thl.fi).

Received: 9 February 2020; Accepted: 1 March 2021
Published online: 17 March 2021

References

1. Jylhä, M. What is self-rated health and why does it predict mortality? Towards a unified conceptual model. Soc. Sci. Med. 69, 307–316 (2009).
2. Idler, E. & Benyamini, Y. Self-rated health and mortality: a review of twenty-seven community studies. J. Health Soc. Behav. 38, 21–37 (1997).
3. Jylhä, M., Volpato, S. & Guralnik, J. M. Self-rated health showed a graded association with frequently used biomarkers in a large population sample. J. Clin. Epidemiol. 59, 465–471 (2006).
4. Fried, L. P. et al. Risk factors for 5-year mortality in older adults: the cardiovascular health study. JAMA 279, 585–592 (1998).
5. Mackenbach, J. P., Simon, J. G., Looman, C. W. & Joung, I. M. Self-assessed health and mortality: could psychosocial factors explain the association? Int. J. Epidemiol. 31, 1162–1168 (2002).
6. Chen, H., Cohen, P. & Kasen, S. Cohort differences in self-rated health: evidence from a three-decade, community-based, longitudinal study of women. Am. J. Epidemiol. 166, 439–446 (2007).
7. Park, S., Ahn, J. & Lee, B. K. Self-rated health showed a graded association with serum HDL-cholesterol in a large population sample. J. Clin. Epidemiol. 59, 465–471 (2006).
8. Fried, L. P. et al. Risk factors for 5-year mortality in older adults: the cardiovascular health study. JAMA 279, 585–592 (1998).
9. Mackenbach, J. P., Simon, J. G., Looman, C. W. & Joung, I. M. Self-assessed health and mortality: could psychosocial factors explain the association? Int. J. Epidemiol. 31, 1162–1168 (2002).
10. Chen, H., Cohen, P. & Kasen, S. Cohort differences in self-rated health: evidence from a three-decade, community-based, longitudinal study of women. Am. J. Epidemiol. 166, 439–446 (2007).
11. Park, S., Ahn, J. & Lee, B. K. Self-rated subjective health status is strongly associated with sociodemographic factors, lifestyle, nutrient intakes, and biochemical indices, but not smoking status: KNHANES 2007–2012. J. Korean Med. Sci. 30, 1279–1287 (2015).
12. Shiro, A., Toker, S., Melamed, S. & Shapira, I. The relationships between self-rated health and serum lipids across time. Int. J. Behav. Med. 19, 73–81 (2012).
13. Tomtén, S. E. & Hostmark, A. T. Self-rated health showed a consistent association with serum HDL-cholesterol in the cross-sectional Oslo Health Study. Int. J. Med. Sci. 4, 278–287 (2007).
14. Nixon Andreasson, A. et al. Associations between leptin and self-rated health in men and women. Gend. Med. 7, 261–269 (2010).
15. Unden, A. et al. Inflammatory cytokines, behaviour and age as determinants of self-rated health in women. Clin. Sci. 112, 363 (2007).
16. Nakata, A., Takahashi, M., Otsuka, Y. & Swanson, N. G. Is self-rated health associated with blood immune markers in healthy individuals? Int. J. Behav. Med. 17, 234–242 (2010).
17. Christian, L. M. et al. Poorer self-rated health is associated with elevated inflammatory markers among older adults. Psychoneuroendocrinology 36, 1495–1504 (2011).
18. Tanno, K. et al. Poor self-rated health is significantly associated with elevated C-reactive protein levels in women, but not in men, in the Japanese general population. J. Psychosom. Res. 73, 225–231 (2012).
19. Leschén-Rubinow, E. et al. Self-rated health is associated with elevated C-reactive protein even among apparently healthy individuals. Isr. Med. Assoc. J. 17, 213–218 (2015).
20. Andreasson, A. N. et al. Psychological well-being and positive affect are associated with subjective health in the general population. J. Health Psychol. 18, 311–320 (2013).
21. Arntzen, E. K., Lekander, M., Morye, J. N. & Segerstrom, S. C. Self-rated health and interleukin-6: longitudinal relationships in older adults. Brain Behav. Immun. 54, 226–232 (2016).
22. Iarczek, M. N. et al. Investigating the associations of self-rated health: heart rate variability is more strongly associated than inflammatory and other frequently used biomarkers in a cross-sectional occupational sample. PLoS ONE 10, e0117196 (2015).
23. Kafij, B. et al. Associations of serum 25-hydroxyvitamin D concentrations with quality of life and self-rated health in an older population. J. Clin. Endocrinol. Metab. 99, 3136–3143 (2014).
24. Tepper, S. et al. Vitamin D status and quality of life in healthy male high-tech employees. Nutrients 8, 366. https://doi.org/10.3390/nu8060366 (2016).
25. Quadt, L., Critchley, H. D. & Garfinkel, S. N. The neurobiology of interception in health and disease. Ann. N. Y. Acad. Sci. 1428, 112–128 (2018).
26. Danziger, R., O’Connor, J. C., Freund, G. G., Johnson, R. W. & Kelley, K. W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46–56 (2008).
Acknowledgements

The authors extend their thanks to all participants from the different study centres in MARK-AGE, CAMB and Health 2000 Survey, for their dedication and continued support. The authors also express their gratitude to the funding bodies and institutions that have supported the project, including the European Commission through the FP7 large-scale integrating project “European Study to Establish Biomarkers of Human Ageing” (MARK-AGE; grant agreement No.: 200880). The Copenhagen Aging and Midlife Biobank was funded by generous grants from the VELUX FOUNDATION (VELUX 26145 and 31539), and this manuscript was prepared in collaboration with the VELUX FOUNDATION (VELUX 26145 and 31539), and this manuscript was prepared in collaboration with

23. Justice, J. N. et al. A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. *Geroscience* **40**, 419–436 (2018).

24. Christakos, S., Dhawan, P., Verstuyf, A., Verlinden, L. & Carmeliet, G. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. *Physiol. Rev.* **96**, 365–408 (2016).

25. Duggal, N. A. Reversing the immune ageing clock: lifestyle modifications and pharmacological interventions. *Biogerontology* **19**, 481–496 (2018).

26. Jääskeläinen, T. et al. Higher serum 25-hydroxyvitamin D concentrations are related to a reduced risk of depression. *Br. J. Nutr.* **113**, 1418–1426 (2015).

27. Autier, P., Boniol, M., Pizot, C. & Mullie, P. Vitamin D status and ill health: a systematic review. *Lancet Diabetes Endocrinol.* **2**, 76–89 (2014).

28. Schottker, B. et al. Is vitamin D deficiency a cause of increased morbidity and mortality at older age or simply an indicator of poor health? *Eur. J. Epidemiol.* **29**, 199–210 (2014).

29. Eisenhauer, B., Natoli, S., Liew, G. & Flood, V. M. Lutein and zeaxanthin—food sources, bioavailability and dietary variety in age-related macular degeneration protection. *Nutrients* **9**, 120. https://doi.org/10.3390/nu9020120.eCollection2017Feb (2017).

30. Lima, V. C., Rosen, R. B. & Farah, M. Macular pigment in retinal health and disease. *Int. J. Retina Vitreous* https://doi.org/10.1186/s40942-016-0044-9 (2016).

31. Feng, M., Rached, F., Kontush, A. & Chapman, M. J. Impact of lipoproteins on atherobiology: emerging insights. *Cardiol. Clin.* **36**, 193–201 (2018).

32. Ziegler, A., Zangemeister-Wittke, U. & Stahl, R. A. Circulating DNA: a new diagnostic gold mine? *Cancer Treat. Rev.* **28**, 255–271 (2002).

33. Saukkonen, K. et al. Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. *Clin. Chem.* **54**, 1000–1007 (2008).

34. Jylhävä, J. et al. Circulating cell-free DNA is associated with cardiometabolic risk factors: the Health 2000 Survey. *Atherosclerosis* **233**, 268–271 (2014).

35. Gogenur, M., Burchartha, J. & Gogenur, I. The role of total cell-free DNA in predicting outcomes among trauma patients in the intensive care unit: a systematic review. *Crit. Care* **21**, 14. https://doi.org/10.1186/s13054-016-1578-9 (2017).

36. Fatouros, I. G. et al. Cell-free plasma DNA as a novel marker of aseptic inflammation severity related to exercise overtraining. *Clin. Chem.* **52**, 1820–1824 (2016).

37. Schwarzenbach, H., Hoon, D. S. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. *Nat. Rev. Cancer.* **11**, 426–437 (2011).

38. Dalle-Donne, I., Rossi, R., Giustarini, D., Milzani, A. & Colombo, R. Protein carbonyl groups as biomarkers of oxidative stress. *Clin. Chim. Acta* **329**, 23–38 (2003).

39. Manderbacka, K., Lundberg, O. & Martikainen, P. Do risk factors and health behaviours contribute to self-ratings of health? *Soc. Sci. Med.* **48**, 1713–1720 (1999).

40. Kaplan, G. A. & Camacho, T. Perceived health and mortality: a nine-year follow-up of the human population laboratory cohort. *Am. J. Epidemiol.* **117**, 292–304 (1983).

41. Stenback, A. Physical health and physical disease as objective fact and subjective experience. *Arch Gen Psychiatry* **11**, 290–301 (1964).

42. Craig, A. D. Interoception: the sense of the physiological condition of the body. *Arch Gen Psychiatry* **11**, 290–301 (1964).

43. Cameron, O. G. Interoception: the inside story—a model for psychosomatic processes. *Arch Gen Psychiatry* **9**, 292–304 (1964).

44. Van den Bergh, O., Witthoft, M., Petersen, S. & Brown, R. J. Symptoms and the body: taking the inferential leap. *Clin. Epidemiol.* **193–201 (2018).*

45. Heistaro, S. Methodology Report: Health 2000 Survey. Publications of the National Public Health Institute. B26/2008. Helsinki, Finland (2008).

46. Moreh, E., Jacobs, J. M. & Stessman, J. Fatigue, function, and mortality in older adults. *J. Gerontol. B Biol. Sci. Med. Sci.* **65**, 887–895 (2010).

47. Hernández, B., Reilly, R. B. & Kenny, R. A. Investigation of multimorbidity and prevalent disease combinations in older Irish adults using network analysis and association rules. *Soc. Rev.* **9**, 14567 (2019).

48. Halonen, P., Raitanen, J., Jämsen, E., Enroth, L. & Jylhä, M. Chronic conditions and multimorbidity in population aged 90 years and over: associations with mortality and long-term care admission. *Age Ageing* **48**, 564–570 (2019).

49. Willadsen, T. G. et al. Multimorbidity and mortality: A 15-year longitudinal registry-based nationwide Danish population study. *Scand J. Comorb*. https://doi.org/10.1177/2235042X18804063 (2018).

50. Bourke, A. et al. MARK-AGE biomarkers of ageing. *Mech. Ageing Dev.* **151**, 1–2 (2015).

51. Moreno-Villanueva, M. et al. MARK-AGE standard operating procedures (SOPs): a successful effort. *Mech. Ageing Dev.* **151**, 18–25 (2015).

52. Lund, R. et al. Cohort profile: the Copenhagen Aging and Midlife Biobank (CAMB). *Int. J. Epidemiol.* **45**, 1044–1053 (2016).

53. Heitano, S. Methodology Report: Health 2000 Survey. Publications of the National Public Health Institute. B26/2008. Helsinki, Finland (2008).
Author contributions
M.J. conceived of the study in consultation with L.K. L.K. conducted the analyses, and the text was written by L.K. and M.J. All other authors, J.R., J.J., A.B., M.M.-V., J.B., O.T., B.G.-L., M.M., A.B., F.P., S.C., E.S.G., E.S., D.G., E.H.J.M.J., M.E.T.D., M.S., W.S., D.W., T.G., N.B., A.S., M.C., C.F., P.E.S., D.C.S.T., C.L., S.K., H.B., Å.M.H., R.L., and M.H. made additional analysis suggestions and provided text/references on specific sections. All authors contributed to the text of the manuscript and reviewed the final submission.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-85668-7.

Correspondence and requests for materials should be addressed to M.J.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021